Oric Pharmaceuticals (NasdaqGS:ORIC) FY Conference Transcript

Summary of Oric Pharmaceuticals FY Conference Call Company Overview - Company: Oric Pharmaceuticals (NasdaqGS:ORIC) - Industry: Clinical stage oncology - Mission: Overcoming Resistance in Cancer - Focus Areas: Prostate cancer, lung cancer, and breast cancer - Clinical Programs: - ORIC-944: Allosteric PRC2 inhibitor for prostate cancer in combination with apalutamide and daralutamide - ORIC-114: Selective brain penetrant EGFR HER2 exon 20 program for non-small cell lung cancer [2][3] Financial Position - Cash and Investments: $436 million as of Q2, providing a runway into the second half of 2028, assuming success in clinical programs [3] Clinical Development Insights - ORIC-944: - Targets AR-dependent tumors transitioning to AR-independent states, aiming to resensitize them to AR inhibitors [4] - Clinical data from competitors (e.g., Pfizer) shows significant improvements in progression-free survival (PFS) with PRC2 inhibitors [6][7] - Pfizer's data indicated a tripling of PFS benefit in certain patient populations, validating the mechanism [7][8] - Physician Feedback: - Positive feedback on the randomized control study by Pfizer, indicating a promising profile for new agents in prostate cancer [10][11] - Comparative Data: - ORIC-944 shows higher PSA response rates and better safety profiles compared to Pfizer's mevrometostat [13][14] - ORIC-944 designed specifically for prostate cancer with optimized drug properties [14][15] Market Opportunity - Prostate Cancer Market: - Significant unmet need with a large patient population; existing AR inhibitors generated $11 billion in sales last year [16][17] - Even with a similar profile to competitors, the market opportunity remains substantial due to the high number of patients [17][18] Phase III Trials - Timeline: Planning to start the first phase III study in the first half of next year, approximately 18 months behind Pfizer [18][32] - Patient Population: Focus on post-abiraterone patients, with expectations for FDA labeling to reflect this [33][34] EGFR Program (ORIC-114) - Upcoming Updates: Data expected at ESMO Asia, focusing on three patient populations: EGFR exon 20, HER2 exon 20, and EGFR atypical [38] - Benchmarks: Expected response rates of 35% for EGFR exon 20 and atypicals, and 50% for HER2 exon 20 in second-line settings [39] Combination Therapy - Amivantamab Collaboration: Exploring combination therapy with Amivantamab, leveraging its success in classical EGFR settings [42][43] - Rationale: Aiming for dual inhibition of EGFR to manage safety and potentially extend PFS and overall survival [43] Conclusion - Oric Pharmaceuticals is positioned to capitalize on significant market opportunities in oncology, particularly in prostate cancer and lung cancer, with promising clinical data and a strong financial position to support ongoing and future trials. The company is focused on differentiating its therapies through optimized drug properties and strategic collaborations.